Achieving Comprehensive Care for Chronic Immune Thrombocytopenia

Activity Overview

Up to 20% of pediatric patients and up to 70% of adult patients with immune thrombocytopenia have chronic disease, persisting for at least 12 months. Though available treatment options have seen some success, they are limited in their ability to address the underlying autoimmune platelet destruction etiology of ITP and often possess negative risk profiles. As a result, patients often live with uncontrolled hematological and non-hematological disease burden, including fatigue and cognitive impairment. Emerging therapies, such as Bruton’s tyrosine kinase inhibitors (BTKi), FcRN blockers, and other strategies, may offer more effective, durable, and safer treatment options to address the multi-faceted burden of ITP. Ensuring patients can access these novel therapies requires efforts to remain up-to-date with their supporting scientific data and understand principles for integrating treatments into practice. Through a dynamic format that integrates evidence-based presentations, panel discussions, and clinical cases, expert faculty participating in this symposium will bring evolving science to life and provide clinical insights to evolving strategies to address hematological and non-hematological ITP manifestations and improve the patient experience.

Target Audience

This activity is intended for Hematologists, Hematologists/Oncologists, NP/PA’s and other HCPs who may be involved in the management of patients with cITP.

Learning Objectives:

• Recognize unmet hematological, quality of life, and long-term health needs of individual living with chronic ITP ​
• Evaluate the MoA and clinical data on BTKi treatments, and other novel disease-targeting treatments, for chronic ITP, considering hematological, safety, and patient-reported outcomes​
• Propose practical strategies that support improved screening and assessment for fatigue, cognitive impairment, and other health related QoL outcomes in chronic ITP ​
• Integrate patient-centered strategies into chronic ITP management plans that foster early intervention to address uncontrolled disease, considering current and emerging therapy options, and support shared decision-making in the second-line treatment setting

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

This activity is supported by an educational grant from Sanofi.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Ph*rm*cy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For physicians, hours of participation are the number of AMA PRA Category 1 Credits™ awarded.

Criteria for Success

Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].

Info: Collaborative Efforts to Assess and Address the Full Spectrum of Patient Needs

Host or Publisher Catalyst Medical Education, LLC